Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ? for the board

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Dec 08, 2023 3:43pm

122 Views

Post# 35775543

RE:RE:RE:RE:? for the board

and deliberate choice of wording... different to confirm... i.e. prove,

ONCY is still mincing words to suggest more than is actually the case... If they had confirmed a biomarker, they would have used exactly that language...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China